{"entity":{"id":"nct07263594","kind":"trial","name":"A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors","aka":[],"tldr":"A phase 1/2 trial of DB-1324 in advanced solid tumours, run by DualityBio Inc., now recruiting.","summary":"A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors is a phase 1/2 interventional study registered as NCT07263594 by DualityBio Inc., with 127 participants planned, started 2026-01-20 and due to reach its primary completion in 2028-12. Interventions recorded: DB-1324.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07263594","url":"https://clinicaltrials.gov/study/NCT07263594"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["dualitybio","gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07263594","phase":"1/2","setting":"A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1324 in Participants With Advanced/Metastatic Gastrointestinal Tumors","sponsor":"DualityBio Inc.","enrolled":127,"outcomes":[]},"route":"/trials/nct07263594/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/"},{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}